VJHemOnc Podcast

The Video Journal of Hematological Oncology (VJHemOnc) podcast covers the latest hematological oncology and hematology news from international experts – from leukemias, lymphomas, MDS and MPNs, to sickle cell, aplastic anemia and rare diseases. Made for healthcare professionals and researchers, we are a global, independent, open-access platform. Listen to the latest news, including cutting-edge trial updates, controversies and opinion. If you enjoy the podcast, please leave us a rating and review! For more news visit www.vjhemonc.com

Updates to the ESMO CLL clinical practice guidelines and implications for relapsed therapy
May 8, 2025 – 19:50
Highlights from iwMyeloma 2025: trial updates and practical considerations
May 2, 2025 – 35:16
Updates to the ESMO CLL clinical practice guidelines: implications for frontline treatment
Apr 25, 2025 – 34:36
Highlights from EBMT 2025: preventing and managing GvHD, harnessing AI in transplant, & more
Apr 17, 2025 – 22:54
Sequencing therapies in R/R NHL: immunotherapy in DLBCL, BTKis in MCL, & more!
Apr 14, 2025 – 46:21
Novel CAR strategies being explored in lymphoma: allogeneic products, trispecific CARs & new manufacturing platforms
Mar 31, 2025 – 18:06
Approaches to optimizing induction therapy in AML: FLT3 inhibitors, menin inhibitors, CPX-351, & more!
Mar 28, 2025 – 23:27
Treating R/R mantle cell lymphoma: the role of BTK inhibitors, combination approaches being explored & overcoming resistance
Mar 24, 2025 – 16:52
Addressing unmet needs in myeloma: early detection, frail/elderly patients, triple-class exposed disease, & more!
Mar 14, 2025 – 27:48
CAR T-cell therapy in ALL: trial updates, novel approaches, & real-world outcomes
Feb 27, 2025 – 18:39
Post-ASH amyloidosis highlights: the ANDROMEDA trial, risk stratification, value of MRD, & more!
Feb 21, 2025 – 13:15
Post-ASH non-malignant highlights: updates in sickle cell disease, thalassemia, and hemophilia
Feb 14, 2025 – 18:28
Post-ASH myeloma highlights: key takeaways for community physicians & trials to look out for in 2025
Feb 6, 2025 – 18:29
Post-ASH AML highlights: novel approaches to frontline therapy, advances with menin inhibitors, & managing FLT3-ITD+ AML
Jan 31, 2025 – 29:00
Post-ASH MPN highlights: key trial updates in MF, novel approaches being explored in R/R disease, & more!
Jan 28, 2025 – 22:21
Post-ASH NHL highlights: novel combinations in the frontline setting and advancements with immunotherapy in the R/R setting
Jan 24, 2025 – 31:20
Post-ASH MDS highlights: managing anemia in LR-MDS and novel approaches to treating HR-MDS
Jan 17, 2025 – 19:03
Post-ASH CLL highlights: BTK inhibitors & degraders, bispecific antibodies, & more!
Jan 10, 2025 – 16:31
Advancing treatment for BPDCN: current therapies, a deep dive into tagraxofusp, & emerging novel agents
Dec 18, 2024 – 28:53
Improving care for patients with SCD: pain management, ongoing projects & unmet needs
Dec 5, 2024 – 16:45
Understanding BPDCN: dermatology and hematology perspectives on presentation, diagnosis, treatment, & multidisciplinary care
Nov 28, 2024 – 34:43
Managing complications associated with WM: Bing-Neel syndrome, acquired von Willebrand disease, & more!
Nov 19, 2024 – 21:37
CAR-T therapies and bispecific antibodies in the treatment of high-risk multiple myeloma: updates from iwHRMM 2024
Nov 12, 2024 – 24:59
The treatment landscape and challenges in rare diseases: BPDCN, CMML, MPN-AP/BP, and VEXAS
Nov 6, 2024 – 22:39
Exploring the role of BTK inhibitors in mantle cell lymphoma: sequencing & managing adverse events
Oct 30, 2024 – 9:30
An update on menin inhibition in AML from iwAL 2024: current data, mechanisms of resistance, & more!
Oct 23, 2024 – 16:35
CAR T-cells and bispecific antibodies in the treatment of NHL: updates from iwNHL 2024
Oct 15, 2024 – 20:31
Prolonging remission in AML: current approaches & future outlooks
Oct 8, 2024 – 31:28
A focus on the use of artificial intelligence to personalize blood cancer care
Sep 30, 2024 – 28:55
A focus on pediatric leukemias: trials, treatments, & challenges
Sep 25, 2024 – 17:44
A focus on the psychosocial impacts of living with blood cancer
Sep 18, 2024 – 36:23
Global perspectives on blood cancers: addressing disparities in awareness, diagnosis, and treatment
Sep 9, 2024 – 18:54
Insights into PV and ET: treating the AYA population, defining goals when treating patients, & more
Sep 2, 2024 – 11:50
Hemophilia updates from ISTH 2024: ongoing clinical trials, emerging gene therapies & remaining challenges
Aug 19, 2024 – 18:42
Inflammation and immune interventions in MDS: targeting STAT, IRAK4, & more
Aug 12, 2024 – 17:29
Updates in the treatment of SCD and thalassemia from EHA 2024: key trial updates, challenges with gene therapies & unmet needs
Aug 5, 2024 – 11:59
Unmet treatment needs in MF: managing prefibrotic disease & thrombocytopenia, novel agents & endpoints for clinical trials
Jul 29, 2024 – 16:01
The role of BTK inhibitors in MCL, ongoing trials & future outlooks: updates from EHA 2024
Jul 22, 2024 – 12:13
Novel developments in lower-risk MDS & important practical considerations when treating patients
Jul 15, 2024 – 51:43
Updates on the use of BCMA-targeting bispecific antibodies in R/R multiple myeloma: insights from EHA & ASCO 2024
Jul 8, 2024 – 16:18
Updates in the treatment of CLL from EHA 2024: BTK and BCL2 inhibitor combinations, BTK degraders, and more
Jul 1, 2024 – 12:10
Highlights from ISA 2024: the importance of early diagnosis in AL amyloidosis, trials in progress & patient selection for SCT
Jun 25, 2024 – 8:43
Treating LR-MDS beyond ESA failure: currently approved agents, novel approaches & future outlooks
Jun 11, 2024 – 46:31
BPDCN treatment and management: CD123-targeting agents, CNS involvement & approaching pediatric/AYA patients
Jun 3, 2024 – 34:39
The future of CAR-T therapy in lymphoma, addressing the risk of secondary malignancy & the optimal sequencing of these agents with bispecific antibodies
May 16, 2024 – 12:34
iwMyeloma 2024 Session I: approaching bone disease, clinical trial updates & the value of MRD as an endpoint in trials
May 10, 2024 – 27:24
Managing anemia in MF, key emerging trials in the UK, and approaching young patients with MPNs
May 3, 2024 – 11:44
Highlights from EBMT 2024: treating & managing GvHD & understanding the role of the gut microbiome
Apr 26, 2024 – 22:51
The importance of cardio-oncology: awareness around the ESC 2022 guidelines & the value of building MDTs
Apr 11, 2024 – 43:52
Exploring the possibility of early interception in smoldering myeloma: novel agents, challenges & advances in risk stratification
Apr 4, 2024 – 22:22